Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

Brian I. Carr; Stuart Carroll; Noemi Muszbek; Kathleen Gondek

doi:10.1111/j.1440-1746.2010.06404.x

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

Brian I. Carr, Stuart Carroll, Noemi Muszbek, Kathleen Gondek

Ente Ospedaliero Specializzato in Gastroenterologia "Saverio de Bellis"

Research output: Contribution to journal › Article › peer-review

Abstract

Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P

Original language	English
Pages (from-to)	1739-1746
Number of pages	8
Journal	Journal of Gastroenterology and Hepatology
Volume	25
Issue number	11
DOIs	https://doi.org/10.1111/j.1440-1746.2010.06404.x
Publication status	Published - 2010

Keywords

Cost-effectiveness
Economic models
Hepatocellular carcinoma
Sorafenib

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.1111/j.1440-1746.2010.06404.x

Cite this

@article{d6063eb9012e4c9ebed75289ee081fb2,

title = "Economic evaluation of sorafenib in unresectable hepatocellular carcinoma",

abstract = "Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P",

keywords = "Cost-effectiveness, Economic models, Hepatocellular carcinoma, Sorafenib",

author = "Carr, {Brian I.} and Stuart Carroll and Noemi Muszbek and Kathleen Gondek",

year = "2010",

doi = "10.1111/j.1440-1746.2010.06404.x",

language = "English",

volume = "25",

pages = "1739--1746",

journal = "Journal of Gastroenterology and Hepatology (Australia)",

issn = "0815-9319",

publisher = "Wiley-Blackwell",

number = "11",

}

TY - JOUR

T1 - Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

AU - Carr, Brian I.

AU - Carroll, Stuart

AU - Muszbek, Noemi

AU - Gondek, Kathleen

PY - 2010

Y1 - 2010

N2 - Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P

AB - Background and Aim: A double-blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly prolonged overall survival compared to placebo (median overall survival=10.7 months vs 7.9 months, P

KW - Cost-effectiveness

KW - Economic models

KW - Hepatocellular carcinoma

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=78149273069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149273069&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2010.06404.x

DO - 10.1111/j.1440-1746.2010.06404.x

M3 - Article

C2 - 21039835

AN - SCOPUS:78149273069

VL - 25

SP - 1739

EP - 1746

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 11

ER -

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this